Oaktree Acquisition Corp. III Life Sciences (OACCW) Liabilities and Shareholders Equity (2024 - 2026)

Oaktree Acquisition Corp. III Life Sciences' Liabilities and Shareholders Equity history runs 3 years deep, the most recent figure standing at $204.8 million for Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 3.85% year-over-year to $204.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $808.4 million (changed N/A YoY) and the FY2025 annual result came in at $203.1 million, up 4.03% from the prior year.
• Liabilities and Shareholders Equity was $204.8 million for Q1 2026 at Oaktree Acquisition Corp. III Life Sciences, up from $203.1 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $204.8 million in Q1 2026 and bottomed at $195.3 million in Q4 2024.
• A 3-year average of $200.1 million and a median of $200.2 million in 2025 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2025 — Liabilities and Shareholders Equity grew 4.03% — and 2026, when it rose 3.85%.
• Oaktree Acquisition Corp. III Life Sciences' Liabilities and Shareholders Equity stood at $195.3 million in 2024, then increased by 4.03% to $203.1 million in 2025, then grew by 0.85% to $204.8 million in 2026.
• Business Quant data shows OACCW's Liabilities and Shareholders Equity at $204.8 million in Q1 2026, $203.1 million in Q4 2025, and $201.2 million in Q3 2025.